Clinical management of primary XXXX : Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.

@entity1 @entity2799 @entity4349 @entity2592 @entity3052
As many options are now available to treat @entity1 with de novo @entity3052 , the Italian Society of Hematology and two affiliated societies (SIES and GITMO) commissioned project to an Expert Panel aimed at developing clinical practice guidelines for @entity3052 treatment. After systematic comprehensive literature review, the Expert Panel formulated recommendations for the management of primary @entity3052 (with the exception of @entity2799 ) and graded them according to the supporting evidence. When evidence was lacking, consensus-based statements have been added. First-line therapy for all newly diagnosed @entity1 eligible for intensive treatment should include one cycle of induction with standard dose @entity2592 and an @entity4349 . After achieving complete remission, @entity1 aged less than 60 years should receive consolidation therapy including high-dose @entity2592 . Myeloablative allogeneic stem cell transplantation from an HLA-compatible sibling should be performed in first complete remission: 1) in @entity1 with intermediate-high risk cytogenetics or who achieved first complete remission after the second course of therapy; 2) in adults less than 40 years with an intermediate-risk; in those aged less than 55 years with either high-risk cytogenetics or who achieved first complete remission after the second course of therapy. Stem cell transplantation from an unrelated donor is recommended to be performed in first complete remission in adults 30 years old or younger, and in @entity1 with very high-risk disease lacking a sibling donor. Alternative donor stem cell transplantation is an option in high-risk @entity1 without a matched donor who urgently need transplantation. @entity1 aged less than 60 years, who either are not candidate for allogeneic stem cell transplantation or lack a donor, are candidates for autologous stem cell transplantation. We describe the results of a systematic literature review and an explicit approach to consensus techniques, which resulted in recommendations for the management of primary non-APL @entity3052 .
